Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mustard Gas | 7 | 2021 | 8 | 3.620 |
Why?
|
| Botulinum Toxins | 9 | 2022 | 38 | 3.360 |
Why?
|
| Botulism | 4 | 2022 | 9 | 2.320 |
Why?
|
| Neurons | 10 | 2017 | 410 | 2.320 |
Why?
|
| Antitoxins | 5 | 2022 | 6 | 2.110 |
Why?
|
| Embryonic Stem Cells | 7 | 2015 | 28 | 2.010 |
Why?
|
| Cornea | 5 | 2021 | 16 | 1.930 |
Why?
|
| Corneal Diseases | 3 | 2020 | 10 | 1.600 |
Why?
|
| Synaptic Transmission | 6 | 2020 | 117 | 1.500 |
Why?
|
| Mice | 19 | 2022 | 2484 | 1.390 |
Why?
|
| Animals | 28 | 2022 | 7541 | 1.390 |
Why?
|
| Chemical Warfare Agents | 4 | 2021 | 14 | 1.300 |
Why?
|
| Synaptosomal-Associated Protein 25 | 4 | 2017 | 6 | 1.160 |
Why?
|
| Endothelium, Corneal | 2 | 2020 | 22 | 1.160 |
Why?
|
| Tetanus Toxin | 2 | 2015 | 6 | 1.030 |
Why?
|
| Paralysis | 3 | 2022 | 13 | 0.990 |
Why?
|
| Potassium Channel Blockers | 2 | 2020 | 9 | 0.860 |
Why?
|
| Corneal Edema | 2 | 2020 | 4 | 0.850 |
Why?
|
| Basement Membrane | 2 | 2020 | 8 | 0.820 |
Why?
|
| Eye Injuries | 2 | 2013 | 16 | 0.800 |
Why?
|
| Rabbits | 7 | 2021 | 197 | 0.780 |
Why?
|
| Diaphragm | 2 | 2018 | 39 | 0.750 |
Why?
|
| Burns, Chemical | 1 | 2020 | 7 | 0.740 |
Why?
|
| Calcium Channels | 2 | 2017 | 57 | 0.720 |
Why?
|
| Presynaptic Terminals | 1 | 2020 | 37 | 0.720 |
Why?
|
| Motor Neurons | 1 | 2020 | 56 | 0.720 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 104 | 0.690 |
Why?
|
| Receptors, Muscarinic | 1 | 2019 | 9 | 0.670 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 31 | 0.660 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2019 | 56 | 0.640 |
Why?
|
| 4-Aminopyridine | 1 | 2018 | 6 | 0.620 |
Why?
|
| Respiratory Paralysis | 1 | 2018 | 3 | 0.620 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 137 | 0.580 |
Why?
|
| Calcium | 6 | 2017 | 307 | 0.550 |
Why?
|
| Neurotoxins | 2 | 2013 | 16 | 0.550 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 1022 | 0.530 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 11 | 0.530 |
Why?
|
| Environmental Exposure | 1 | 2016 | 91 | 0.510 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 28 | 0.510 |
Why?
|
| Glutamic Acid | 2 | 2012 | 47 | 0.500 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 173 | 0.500 |
Why?
|
| Spider Venoms | 2 | 2012 | 3 | 0.490 |
Why?
|
| Computational Biology | 1 | 2015 | 91 | 0.490 |
Why?
|
| Cell Differentiation | 6 | 2015 | 469 | 0.490 |
Why?
|
| Organ Culture Techniques | 3 | 2019 | 39 | 0.470 |
Why?
|
| Stem Cells | 2 | 2014 | 313 | 0.450 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2019 | 32 | 0.450 |
Why?
|
| Toxicology | 1 | 2012 | 6 | 0.430 |
Why?
|
| Keratitis | 1 | 2012 | 3 | 0.420 |
Why?
|
| Disease Progression | 4 | 2020 | 594 | 0.420 |
Why?
|
| Benzimidazoles | 1 | 2012 | 28 | 0.420 |
Why?
|
| Molecular Imaging | 1 | 2012 | 20 | 0.410 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 48 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 633 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 767 | 0.370 |
Why?
|
| Thymosin | 1 | 2010 | 1 | 0.360 |
Why?
|
| Rats | 4 | 2022 | 1595 | 0.340 |
Why?
|
| Plastids | 1 | 2006 | 1 | 0.280 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2006 | 1 | 0.280 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2006 | 2 | 0.280 |
Why?
|
| Plants | 1 | 2006 | 7 | 0.280 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2006 | 14 | 0.280 |
Why?
|
| Time Factors | 3 | 2020 | 2149 | 0.270 |
Why?
|
| Synapses | 3 | 2017 | 83 | 0.260 |
Why?
|
| Female | 9 | 2021 | 19959 | 0.250 |
Why?
|
| Cells, Cultured | 4 | 2017 | 833 | 0.250 |
Why?
|
| Microscopy, Confocal | 3 | 2017 | 65 | 0.240 |
Why?
|
| Humans | 11 | 2020 | 32005 | 0.240 |
Why?
|
| Cell Membrane Permeability | 2 | 2013 | 18 | 0.220 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 495 | 0.220 |
Why?
|
| Lethal Dose 50 | 2 | 2020 | 4 | 0.210 |
Why?
|
| Antidotes | 1 | 2022 | 2 | 0.210 |
Why?
|
| Epithelial Cells | 2 | 2014 | 141 | 0.210 |
Why?
|
| Neurogenesis | 2 | 2012 | 16 | 0.200 |
Why?
|
| Cell Line | 2 | 2013 | 435 | 0.200 |
Why?
|
| Protein Transport | 1 | 2020 | 74 | 0.180 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 276 | 0.180 |
Why?
|
| Random Allocation | 2 | 2019 | 226 | 0.180 |
Why?
|
| Drug Design | 1 | 2020 | 43 | 0.170 |
Why?
|
| Wound Healing | 2 | 2012 | 185 | 0.170 |
Why?
|
| Intercellular Junctions | 1 | 1999 | 1 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 45 | 0.170 |
Why?
|
| Cadherins | 1 | 1999 | 26 | 0.170 |
Why?
|
| Soman | 1 | 2019 | 3 | 0.170 |
Why?
|
| Trans-Activators | 1 | 1999 | 46 | 0.170 |
Why?
|
| Muscarinic Antagonists | 1 | 2019 | 14 | 0.170 |
Why?
|
| Phrenic Nerve | 1 | 2017 | 4 | 0.150 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 72 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 21 | 0.140 |
Why?
|
| Volatilization | 1 | 2016 | 5 | 0.140 |
Why?
|
| Dizocilpine Maleate | 1 | 2015 | 7 | 0.130 |
Why?
|
| SNARE Proteins | 1 | 2015 | 4 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 519 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 120 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 41 | 0.130 |
Why?
|
| Male | 4 | 2019 | 19165 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2265 | 0.120 |
Why?
|
| Contact Lenses | 1 | 2014 | 3 | 0.120 |
Why?
|
| Limbus Corneae | 1 | 2014 | 7 | 0.120 |
Why?
|
| Models, Biological | 2 | 2011 | 392 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 322 | 0.110 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 98 | 0.110 |
Why?
|
| Glutamates | 1 | 2013 | 11 | 0.110 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 27 | 0.110 |
Why?
|
| Cell Size | 1 | 2013 | 38 | 0.110 |
Why?
|
| Tretinoin | 1 | 2013 | 34 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 36 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 762 | 0.110 |
Why?
|
| Cell Nucleus Size | 1 | 2012 | 1 | 0.110 |
Why?
|
| Staurosporine | 1 | 2012 | 3 | 0.110 |
Why?
|
| Aqueous Humor | 1 | 2012 | 3 | 0.110 |
Why?
|
| Organic Chemicals | 1 | 2012 | 7 | 0.110 |
Why?
|
| Necrosis | 2 | 2010 | 53 | 0.100 |
Why?
|
| Proteomics | 1 | 2013 | 94 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 88 | 0.100 |
Why?
|
| Cell Death | 1 | 2012 | 77 | 0.100 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 28 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 209 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 104 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2012 | 108 | 0.100 |
Why?
|
| Cell Survival | 1 | 2012 | 284 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2011 | 51 | 0.100 |
Why?
|
| Acute Disease | 1 | 2012 | 253 | 0.100 |
Why?
|
| United States | 1 | 2020 | 3939 | 0.090 |
Why?
|
| Exocytosis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 40 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 40 | 0.090 |
Why?
|
| Physiological Phenomena | 1 | 2010 | 1 | 0.090 |
Why?
|
| Eye | 1 | 2010 | 15 | 0.090 |
Why?
|
| Intestine, Small | 2 | 2006 | 40 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 608 | 0.080 |
Why?
|
| Chorion | 1 | 2006 | 9 | 0.070 |
Why?
|
| DNA, Chloroplast | 1 | 2006 | 1 | 0.070 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2006 | 8 | 0.070 |
Why?
|
| Intestinal Obstruction | 1 | 2006 | 11 | 0.070 |
Why?
|
| Sequence Alignment | 1 | 2006 | 60 | 0.070 |
Why?
|
| Phylogeny | 1 | 2006 | 56 | 0.070 |
Why?
|
| Nucleic Acid Conformation | 1 | 2006 | 48 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 56 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2006 | 38 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 137 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 109 | 0.070 |
Why?
|
| Progesterone | 1 | 2006 | 101 | 0.070 |
Why?
|
| Fatty Acids, Volatile | 1 | 2006 | 9 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 198 | 0.070 |
Why?
|
| Glutamine | 1 | 2006 | 9 | 0.070 |
Why?
|
| Base Sequence | 1 | 2006 | 252 | 0.070 |
Why?
|
| Mucositis | 1 | 2006 | 8 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 359 | 0.070 |
Why?
|
| Ischemia | 1 | 2006 | 98 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 49 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 64 | 0.060 |
Why?
|
| Methotrexate | 1 | 2006 | 64 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2006 | 247 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 71 | 0.060 |
Why?
|
| RNA | 1 | 2022 | 92 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 22 | 0.040 |
Why?
|
| Protein Folding | 1 | 2020 | 29 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 66 | 0.040 |
Why?
|
| Catenins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Desmoplakins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 17 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 1999 | 18 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 15 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 70 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 96 | 0.040 |
Why?
|
| Actins | 1 | 1999 | 51 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 80 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 1999 | 99 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 43 | 0.040 |
Why?
|
| Binding Sites | 1 | 1999 | 130 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2020 | 193 | 0.040 |
Why?
|
| beta Catenin | 1 | 1999 | 37 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 1999 | 49 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 1999 | 108 | 0.040 |
Why?
|
| Protein Binding | 1 | 1999 | 201 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 78 | 0.040 |
Why?
|
| Phosphorylation | 1 | 1999 | 229 | 0.040 |
Why?
|
| Syntaxin 1 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Dimerization | 1 | 2017 | 23 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 285 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 18 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2014 | 14 | 0.030 |
Why?
|
| Corneal Transplantation | 1 | 2014 | 14 | 0.030 |
Why?
|
| Phosgene | 1 | 2013 | 1 | 0.030 |
Why?
|
| Synapsins | 1 | 2013 | 2 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 2013 | 5 | 0.030 |
Why?
|
| Calcium Channels, N-Type | 1 | 2013 | 3 | 0.030 |
Why?
|
| Calcimycin | 1 | 2013 | 6 | 0.030 |
Why?
|
| Tritium | 1 | 2013 | 14 | 0.030 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tubulin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 26 | 0.030 |
Why?
|
| Glycine | 1 | 2013 | 27 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 169 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 2013 | 22 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 48 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2013 | 31 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 463 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 726 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 93 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2006 | 53 | 0.020 |
Why?
|
| Arteries | 1 | 2006 | 67 | 0.020 |
Why?
|
| ROC Curve | 1 | 2006 | 164 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 133 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 210 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 582 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2006 | 185 | 0.010 |
Why?
|
| Body Weight | 1 | 2006 | 310 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 391 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 997 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 10301 | 0.010 |
Why?
|
| Middle Aged | 1 | 2006 | 11817 | 0.010 |
Why?
|